This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Høgåsen, K Articles by Brandtzaeg, P Search for Related Content PubMed PubMed Citation Articles by Høgåsen, K Articles by Brandtzaeg, P

research-article

Low levels of vitronectin and clusterin in acute meningococcal disease are closely associated with formation of the terminal-complement complex and the vitronectin-thrombin-antithrombin complex.

Department of Immunology and Transfusion Medicine, Nordland Central Hospital, Bodø, Norway.

ABSTRACT

Patients with terminal complement deficiencies and thus impaired lytic efficiency have a highly increased likelihood of contracting invasive meningococcal infections but generally experience a mild disease course. Deficiencies of lysis inhibitors might therefore be associated with severe disease. We have quantified the complement lysis inhibitors vitronectin and clusterin, as well as complexes containing the proteins, in plasma from patients with acute meningococcal disease. At hospital admission, the median vitronectin concentrations were 0.10 (range, 0.04 to 0.17) g/liter in 10 septic patients and 0.19 (0.09 to 0.47) g/liter in 14 nonseptic patients (P = 0.001). The corresponding clusterin concentrations were 0.09 (0.01 to 0.13) and 0.14 (0.06 to 0.29) g/liter (P = 0.005). The vitronectin-thrombin-antithrombin complex concentration was 1.8 (0.22 to 35.6) arbitrary units (AU)/ml in septic patients, but the complex was not detectable in most nonseptic patients (< 0.10 to 0.16 AU/ml) (P < 0.0001). The corresponding levels of the terminal complement complex (contains vitronectin and clusterin) were 4.4 (3.6 to 20.1) and 2.6 (1.6 to 4.7) AU/ml (P = 0.0005). We found no evidence of constitutively low levels of vitronectin or clusterin in patients contracting meningococcal disease. The low levels of the proteins may partly be explained by hemodilution, extravasation, and increased consumption due to incorporation into complexes which are quickly removed from circulation.

This article has been cited by other articles:

• Kalenka, A., Feldmann, R. E. Jr, Otero, K., Maurer, M. H., Waschke, K. F., Fiedler, F. (2006). Changes in the Serum Proteome of Patients with Sepsis and Septic Shock. Anesth. Analg. 103: 1522-1526 [Abstract] [Full Text]  
• Brandtzaeg, P., Bjerre, A., Ovstebo, R., Brusletto, B., Joo, G. B., Kierulf, P. (2001). Invited review: Neisseria meningitidis lipopolysaccharides in human pathology. Innate Immunity 7: 401-420 [Abstract]  
• van Deuren, M., Brandtzaeg, P., van der Meer, J. W. M. (2000). Update on Meningococcal Disease with Emphasis on Pathogenesis and Clinical Management. Clin. Microbiol. Rev. 13: 144-166 [Abstract] [Full Text]  
• Moen, O., Fosse, E., Brockmeier, V., Andersson, C., Mollnes, T. E., Hogasen, K., Venge, P. (1995). Disparity in Blood Activation by Two Different Heparin-Coated Cardiopulmonary Bypass Systems. Ann. Thorac. Surg. 60: 1317-1323 [Abstract] [Full Text]